Victory Capital Management Inc. Sells 151,152 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Victory Capital Management Inc. reduced its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 21.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 559,536 shares of the specialty pharmaceutical company's stock after selling 151,152 shares during the quarter. Victory Capital Management Inc. owned 1.73% of Collegium Pharmaceutical worth $16,031,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Nisa Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after acquiring an additional 483 shares in the last quarter. Foundry Partners LLC boosted its position in shares of Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company's stock worth $610,000 after buying an additional 509 shares during the period. Caprock Group LLC boosted its position in shares of Collegium Pharmaceutical by 6.7% during the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock worth $249,000 after buying an additional 543 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after buying an additional 642 shares during the period.

Remove Ads

Analysts Set New Price Targets

COLL has been the subject of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Stock Up 1.2 %

NASDAQ COLL traded up $0.36 during trading hours on Friday, hitting $29.46. 388,648 shares of the company traded hands, compared to its average volume of 416,204. The business's 50-day moving average is $30.85 and its 200-day moving average is $32.96. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a market capitalization of $927.58 million, a price-to-earnings ratio of 12.70 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 1,949 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,961 shares of company stock worth $3,146,634 over the last 90 days. Company insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.